Kim Kamdar, Ph.D. is a Managing Partner with Medical Excellence Capital. Kim has been involved in cutting edge therapeutic start-ups and companies with promising molecular and companion diagnostics to support personalized medicine for over 20 years. Kim has helped to create and served on the board of over a dozen companies. She was founding CEO for Truvian Sciences where she remains Chair. Kim has also helped to create Seraphina Therapeutics and currently serves as Chair. She was the Founding CEO for Obalon Therapeutics (NASDAQ: OBLN) and Aspen Neuroscience. Kim was an early investor and helped to create companies including Syndax Pharmaceuticals (NASDAQ: SNDX), Singular Genomics (NASDAQ: OMIC) and Pleno. Additional investments and BOD memberships include Alume Biosciences, EPIC Sciences, Evofem Biosciences (NASDAQ: EVFM) and Sera Prognostics (NASDAQ: SERA).

Kim was involved with Ariosa Diagnostics until the company was sold to Roche in January 2015 for $625MM, Omniome until the company was sold to Pacific Bioscience (NASDAQ: PACB) in September 2021 for $800M, Corthera until the company was sold to Novartis in February 2010 for $620MM and BiPar Sciences until that company was sold to Sanofi in April 2009 for $500MM.

Kim has been part of Domain Associates since 2005 and a Partner since 2010. Prior to Domain, Kim was a Kauffman Fellow at MPM Capital where she participated in the firm’s investments in Transform Pharmaceuticals, Portola Pharmaceuticals and Affymax. Previous to that, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.

Kim is currently an Advisory Board Member for Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and an advisor and on the Investment Committee for Adjuvant Capital, a Bill and Melinda Gates Foundation sponsored venture fund focused on global health. Kim also serves as a BOD member for Connect San Diego and Access Youth Academy, a non-profit helping to transform the lives of underserved youth through academic enrichment, health and wellness, social responsibility, and leadership through squash.

Venture Capital, Corporate Venturing, Science, Health, Healthcare, Healthcare Futurism, Gene Therapy Genetics, Genealogy, Pharmaceutical, Biotechnology, Biology, Bioengineering, Molecular Biology, Chemistry, Female Leadership,